1. Introduction {#sec1-jcm-09-02283}
===============

Colorectal cancer (CRC) is one of the most common cancers in the United States \[[@B1-jcm-09-02283]\]. Approximately 130,000 CRC patients are newly diagnosed each year, and nearly 30% of these patients develop distant metastasis. In 2017, a total of 50,260 CRC patients died in the United States \[[@B2-jcm-09-02283],[@B3-jcm-09-02283]\]. Following the emergence of monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), cytotoxic chemotherapy plus targeted monoclonal antibody has been recommended as the standard treatment for metastatic CRC around the world \[[@B4-jcm-09-02283]\]. Anti-EGFR monoclonal antibody is recommended for RAS--wild or left colon cancers, and VEGF antibody is recommended for RAS-mutant or right colon cancers. Accordingly, the mutational status of EGFR downstream signaling effectors, especially KRAS, must be screened to determine the ideal course of targeted therapy.

KRAS is a major predictive marker for anti-EGFR treatment, and determination of KRAS mutational status is crucial for successful management of CRC patients. Mutation of KRAS is detected in 35--45% of CRC patients, and most of these mutations affect codons 12 and 13 \[[@B5-jcm-09-02283]\]. Multiple KRAS detection methods have been investigated, including direct sequencing, pyrosequencing, polymerase chain reaction (PCR) with peptide nucleic acid (PNA)-mediated clamping, and next-generation sequencing (NGS) \[[@B6-jcm-09-02283],[@B7-jcm-09-02283],[@B8-jcm-09-02283]\]. To detect KRAS mutation in a more effective manner, effort has been devoted to decreasing the amount of tumor material required, and optimizing the sensitivity and specificity of testing.

Digital droplet PCR (ddPCR) is a recently developed sequencing method capable of sensitively detecting target DNA in varying backgrounds of wild-type DNA in a small amount of material \[[@B9-jcm-09-02283]\]. By partitioning DNA into a large number of droplets, ddPCR can provide absolute quantification and detect target DNA in a much higher background of non-target (usually wild-type) DNA. Due to its technological advantages, ddPCR has been adopted for testing of KRAS mutation in patient samples \[[@B4-jcm-09-02283]\]. However, the clinical performance of ddPCR-based KRAS mutation detection in CRC has not been carefully evaluated.

In this study, we sought to validate a ddPCR platform for detection of KRAS^G12/G13^ mutation (KRAS codon 12 and codon 13) using CRC patient tissue samples. KRAS^G12/G13^ mutant allele frequency (MAF) generated by ddPCR was measured repeatedly to assess the consistency of ddPCR. Receiver operating characteristic (ROC) curves were constructed based on the MAF to determine KRAS^G12/G13^ mutational status with the optimal cutoff value. The diagnostic performance of ddPCR was compared with gold standard methods for KRAS^G12/G13^ mutational analysis: Sanger sequencing and PNA-clamping assay (PCR with PNA-mediated clamping).

2. Materials and Methods {#sec2-jcm-09-02283}
========================

2.1. Sample Selection and DNA Isolation {#sec2dot1-jcm-09-02283}
---------------------------------------

This study was performed using 81 formalin-fixed paraffin-embedded (FFPE) surgically resected colorectal adenocarcinoma (CRAC) tissue samples collected at a single institutional center (Chungnam National University Hospital, Daejeon, South Korea) from January 2014 to December 2017. Tissue samples included primary and metastatic (liver, lung, and ovary) tissues from CRAC patients. Hematoxylin/eosin-stained slides of selected cases were pathologically reviewed by two pathologists (M-KY and GEB), and the most representative areas were selected. Twenty non-neoplastic colon FFPE tissue samples (10 samples acquired from tissues located more than 5 cm apart from the CRAC and 10 samples from surgically resected colon due to inflammation) were included for negative control. Sixteen serums from healthy persons were also included negative control.

Twenty-micron thick sections of FFPE samples were prepared and deparaffinized in xylene. DNA was isolated using the QIAamp DNA FFPE Tissue Kit and QIAamp Circulating Nucleic Acid kit (QIAGEN Korea, Seoul, South Korea). All extracted DNA was diluted to 10 ng/μL. Extracted DNAs were evaluated for KRAS^G12/G13^ mutation using ddPCR, Sanger sequencing, and PNA-clamping PCR. All bio-specimens and data used for this study were provided by the Biobank of Chungnam National University Hospital, a member of the Korea Biobank Network. The study was approved by Chungnam National University Hospital institutional review board (IRB file no. 2018-10-012-001). The study was retrospective, and a waiver of consent was approved by the Institutional Review Board.

2.2. Droplet Digital Polymerase Chain Reaction (ddPCR) {#sec2dot2-jcm-09-02283}
------------------------------------------------------

Extracted DNA from CRAC tissue samples was tested with ddPCR (QX200; Bio-Rad, Hercules, CA, USA) using the ddPCR Bio-Rad KRAS^G12/G13^ multiplex kit (\#1863506) for screening of codons 12/13 ([Figure 1](#jcm-09-02283-f001){ref-type="fig"}A). Reaction mixtures (final volume, 20 µL) consisted of extracted DNA (1 μL), 2× SuperMix for probe (10 μL), KRAS screening probe (1 μL), and distilled water (8 μL). The mixture was loaded into a disposable droplet generator cartridge (Bio-Rad), and 70 μL droplet generation oil for primer (Bio-Rad) was loaded into each of the eight oil wells. The cartridge was then placed inside the QX200 droplet generator (Bio-Rad), which partitioned each tissue sample into \~22,000 droplets per tissue sample. When droplet generation was completed, the droplets were transferred to a 96-well PCR plate. The plate was heat-sealed with foil and placed in a conventional thermal cycler (T100, Bio-Rad) using the following reaction conditions: 95 °C for 10 min (1 cycle); 94 °C for 30 s and 55 °C for 1 min (40 cycles); 98 °C for 10 min (1 cycle); and 4 °C hold. Cycled droplets were read individually on a QX200 droplet-reader (Bio-Rad). Samples were transferred to the QX200 for fluorescence measurement of mutant probe labeled with 6-fluorescein amidite (FAM) and wild-type probe labeled with hexachlorofluorescein (HEX). DNA from SW480 cell line (KRAS G12V mutation) served as a positive control; DNA from the leukocytes of the heathy persons, HEK cell line, and distilled water were used as negative control, respectively.

The QuantaSoft software (version 1.7; Bio-Rad) classifies droplets by first determining a fluorescence threshold ([Figure 1](#jcm-09-02283-f001){ref-type="fig"}B). Some droplets were in the intermediate "rain" (gray droplets), which had fluorescence ranging between those of explicit positive and negative droplets. The dashed horizontal line in [Figure 1](#jcm-09-02283-f001){ref-type="fig"}B indicates a fluorescence value greater than the set threshold; these were considered positive \[[@B10-jcm-09-02283]\]. After analyzing the number of positive and negative fluorescence signals in droplets, MAF was calculated as the percentage of mutant droplets relative to the total (mutant + wild-type).

2.3. Sanger Sequencing {#sec2dot3-jcm-09-02283}
----------------------

Extracted DNA (20 ng) from CRAC tissue samples were sent for Sanger sequencing (Macrogen, Seoul, Korea).

For mutation analyses in codons 12 and 13 of the KRAS gene, primer sequences for exon 2, 5′-GTAAAACGACGGCCAGTGTGTGACATGTTCTAATATAGTCA-3′(forward) and 5′-GCGGATAA CAATTTCACACAGGGAATGGTCCTGCACCAGTAA-3′ (reverse) and for exon 3, 5′-TAATA CGACTCACTATAGGGGTGCTTAGTGGCCATTTGTC-3′ (forward) and 5′-GCTAGTTATTGC TCAGCGGTATGCATGGCATTAGCAAAG -3′ (reverse) were utilized for the PCR reaction.

PCR amplification conditions were as follows: 95 °C 5 min; 95 °C 30 s, 60 °C 30 s, 72 °C 1 min for 35 cycles; 72 °C 7 min. PCR products were purified using Millipore plate MSNU030 (Millipore SAS, Molsheim, France). The purified PCR products were then Sanger-sequenced with the BigDye terminator v3.1 sequencing kit and a 3730xl automated sequencer (Applied Biosystems, Foster City, CA). Nucleotide sequence data were analyzed with Variant reporter computer software version 1.1 (Applied Biosystems, Foster City, CA, USA).

2.4. Peptide Nucleic Acid (PNA)-Clamping Assay (PCR with PNA-Mediated Clamping) {#sec2dot4-jcm-09-02283}
-------------------------------------------------------------------------------

Extracted DNA (7 μL) from CRAC tissue samples was tested by PNA-clamping assay using the PNA clamp KRAS mutation detection kit (version 4; Panagene, Daejeon, South Korea) for screening of codons 12/13/59/61/117/146. Reaction mixtures contained 7 µL DNA template, 3 μL of each PNA mix, and 10 μL of 2× premix, and amplification was performed in a CFX96 real-time PCR instrument (Bio-Rad) with the following thermal program: pre-incubation at 94 °C for 5 min, followed by 40 cycles of amplification at 94 °C for 30 s (s), 70 °C for 30 s, 63 °C for 30 s, and 72 °C for 30 s.

The efficiency of PNA-mediated PCR clamping was determined by measuring the threshold cycle (Ct) value. The Ct values for the control and mutation assays were obtained by observing the SYBR Green amplification plots. The delta Ct (ΔCt) value was calculated (\[Control Ct\] − \[Sample Ct\] = ΔCt) and the cutoff ΔCt was defined as 2 for the all mutations.

2.5. Statistical Analysis {#sec2dot5-jcm-09-02283}
-------------------------

To develop ROC curves for KRAS^G12/G13^ detection by the ddPCR platform, cases in which mutations were detected by Sanger sequencing were considered as positive references. KRAS^G12/G13^ mutation detection by ddPCR was performed three times (first, second, and third), and the mean MAF of KRAS^G12/G13^ was used to develop ROC curve. Internal consistency of the scales was assessed by Cronbach's alpha via the intraclass correlation coefficient and kappa coefficient.

Diagnostic value (sensitivity, specificity, positive predictive value, and negative predictive value) was calculated for the detection of KRAS^G12/G13^ mutation by ddPCR, Sanger sequencing, and PNA-clamping assay. All statistical analyses were performed using SPSS version 26.0 for Windows (SPSS Inc., Chicago, IL, USA) and MedCalc version 19.2.0 for Windows (MedCalc Software Ltd., Ostend, Belgium).

3. Results {#sec3-jcm-09-02283}
==========

3.1. Detection of KRAS^G12/G13^ Mutation by ddPCR, Sanger Sequencing and PNA Clamping Assay {#sec3dot1-jcm-09-02283}
-------------------------------------------------------------------------------------------

The ddPCR platform used the QuantaSoft software to measure the numbers of positive and negative droplets in each well. A total number of generated droplets ranged from 10,461 to 30,796 per well (mean: 18,182). Samples with fewer than 10,000 generated droplets were excluded from analysis. Threshold horizontal lines were set at 9474 for channel 1 (KRAS^G12/G13^ mutant) 3480 for channel 2 (KRAS^G12/G13^ wild) ([Figure 1](#jcm-09-02283-f001){ref-type="fig"}B). MAF was calculated as the percentage of mutant droplets relative to all (mutant + wild-type) droplets.

Sixteen serums from healthy persons showed no KRAS^G12/G13^ mutant droplets. Twenty non-neoplastic colon tissue samples showed 0 to 6 KRAS^G12/G13^ mutant droplets and the MAF were 0 to 0.55% (mean: 0.06%). A total of 81 CRAC tissue samples showed KRAS^G12/G13^ mutant droplets from 0 to 1121 droplets and the MAF were 0 to 81.17% (mean: 11.13%).

Sixteen serums from healthy persons and 20 non-neoplastic colon tissue samples were all KRAS^G12/G13^ wild type by Sanger sequencing and PNA clamping assay. A total of 81 CRAC, 51 (63%) CRAC were KRAS^G12/G13^ wild type and 30 (37%) CRAC were KRAS^G12/G13^ mutant (23 cases of codon12 and 7 cases of codon 13) by Sanger sequencing. A total of 81 CRAC, 48 (59%) CRAC were KRAS^G12/G13^ wild type and 33 (41%) CRAC were KRAS^G12/G13^ mutant (27 cases of codon12 and 6 cases of codon 13) by PNA clamping assay.

3.2. Receiver Operating Characteristic (ROC) Curves in Determination of KRAS^G12/G13^ Mutation by ddPCR {#sec3dot2-jcm-09-02283}
-------------------------------------------------------------------------------------------------------

To determine the mutational status of KRAS^G12/G13^ by ddPCR as "mutant" or "wild-type," a cutoff value for MAF was required. To this end, we generated ROC curves to determine KRAS^G12/G13^ mutational status from MAFs generated by ddPCR ([Figure 2](#jcm-09-02283-f002){ref-type="fig"}). To develop ROC curves for KRAS^G12/G13^ detection by the ddPCR platform, cases in which mutations were detected by Sanger sequencing were considered as positive references. The negative references were used (A) non-neoplastic colon; (B) non-neoplastic colon and KRAS^G12/G13^ wild-type CRAC by Sanger sequencing ([Figure 2](#jcm-09-02283-f002){ref-type="fig"}). The AUC (area under the curve) of the A (negative reference: non-neoplastic colon) was 0.993 and optimal cutoff was 0.12% (*p* \< 0.001) ([Figure 2](#jcm-09-02283-f002){ref-type="fig"}A). The AUC of the B (negative reference: non-neoplastic colon and KRAS^G12/G13^ wild CRAC by Sanger sequencing) was 0.943 and optimal cutoff was 7.9% (*p* \< 0.001) ([Figure 2](#jcm-09-02283-f002){ref-type="fig"}B).

We assessed the diagnostic value of ddPCR KRAS^G12/G13^ mutation using the calculated cutoffs ([Table 1](#jcm-09-02283-t001){ref-type="table"}). Sensitivity and specificity were 100% and 30.91% with 0.12% MAF cutoff; 84.38% and 97.96% for the ddPCR 7.9% MAF cutoff. The optimal cutoff value of the MAF was determined to be 7.9%, which yielded a maximal increase in the sensitivity and specificity.

3.3. Repetitive Measurement of KRAS^G12/G13^ Mutation by ddPCR {#sec3dot3-jcm-09-02283}
--------------------------------------------------------------

To assess the reproducibility of the ddPCR platform, we measured three sets of KRAS^G12/G13^ MAFs in CRAC tissue samples using the KRAS^G12/G13^ mutation multiplex kit. The time interval between measurements was 3 months. The means of the three MAF results were calculated. The pooled intraclass correlation (ICC) coefficient for the three sets of MAFs and the mean was 0.956 (*p* \< 0.001), which is an excellent concordance rate.

With 7.9% MAF cutoff generated by the ROC curves was used to assign "mutant" or "wild-type" KRAS^G12/G13^ mutation status to the CRAC tissue samples ([Table 2](#jcm-09-02283-t002){ref-type="table"}). In all, 74 of 81 cases (91%) yielded concordant results. The remaining 7 cases (8%) yielded discrepant results ([Table 2](#jcm-09-02283-t002){ref-type="table"}, \*).

Next, we assessed the diagnostic value of repetitive measurements of ddPCR KRAS^G12/G13^ mutation using the calculated optimal cutoffs ([Table 3](#jcm-09-02283-t003){ref-type="table"}). Sensitivity and specificity were, respectively, 71.88% and 100% for the first measurement; 84.38% and 97.96% for the second measurement; 84.38% and 93.88% for the third measurement; and 84.38% and 97.96% for the mean.

3.4. Comparison of KRAS^G12/G13^ Mutation Analysis by ddPCR, Sanger Sequencing, and PNA-Clamping Assay {#sec3dot4-jcm-09-02283}
------------------------------------------------------------------------------------------------------

We validated KRAS^G12/G13^ mutation status in CRAC tissue samples by ddPCR, Sanger sequencing, and PNA-clamping assay ([Table 4](#jcm-09-02283-t004){ref-type="table"}). Twenty-eight KRAS^G12/G13^ mutant cases were detected by ddPCR; MAF ranged from 7.9% to 81.2% (the mean mutant MAF = 30.9%). In 53 KRAS^G12/G13^ wild-type cases, MAF ranged from 0% to 7.53% (the mean of wild-type MAF = 0.67%).

Comparing two methods to detect KRAS^G12/G13^ mutation, the concordant rate of the ddPCR and Sanger sequencing was 93% (75/83); the ddPCR and PNA-clamping assay was 89% (72/81); Sanger sequencing and PNA-clamping assay was 81% (66/81). Six discordant cases (T23, T29, T38, T42, T48 and T54) were identified between ddPCR and Sanger sequencing. Except 1 case (T54), Sanger sequencing detected KRAS^G12/G13^ mutation, otherwise, ddPCR (all 3 tests were wild type) and PNA clamping assay did not detect KRAS^G12/G13^ mutation. The MAF of discordant cases were 0.17%, 0.26%, 0.39%, 0.54%, 1.78%, and 7.9%. Nine discordant cases (T15, T47, T49-T53, T59 and T61) were identified between ddPCR and PNA clamping assay. Except 2 cases (T59, T61), PNA clamping assay detected KRAS^G12/G13^ mutation, otherwise, ddPCR and Sanger sequencing did not detect KRAS^G12/G13^ mutation. The MAF of discordant cases were 0.11%, 1.04%, 2.14%, 2.42%, 4%, 5.48%, 7.53%, 18.2%, and 19.36%. T52 (MAF = 2.17%, 5.62%, and 8.65%) and T53 (MAF = 3.61%, 9.11%, and 9.87%) cases showed discordant results in 3 repetitive ddPCR results.

For comparative analysis, cases in which KRAS^G12/G13^ mutation was detected by two or more methods were defined as positive references. Twenty-eight of 81 CRAC tissue samples (35%) harbored the KRAS^G12/G13^ mutation from the results of positive references. Fifteen of 81 cases (18.5%) yielded discrepant results ([Table 4](#jcm-09-02283-t004){ref-type="table"}, \*). ddPCR generated no discordant cases relative to the positive reference. The Sanger sequencing assay yielded discordant results in 6/15 cases and PNA-clamping assay in 9/15 cases. The concordance rate (κ value) between ddPCR and the positive reference was 1.000 (*p* \< 0.001); the κ value was 0.842 (*p* \< 0.001) for the Sanger sequencing; 0.764 (*p* \< 0.001) for PNA-clamping assay. The κ value of ddPCR with the Sanger sequencing was 0.842 (*p* \< 0.001) and 0.764 (*p* \< 0.001) with PNA-clamping assay.

Comparison of the diagnostic performance of ddPCR, Sanger sequencing, and PNA-clamping assay for detection of KRAS^G12/G13^ ([Table 5](#jcm-09-02283-t005){ref-type="table"}) indicated that the sensitivity and specificity of the ddPCR test were 100% and 100%, respectively, making it superior to the other two methods (Sanger sequencing: 96.43% and 90.57% respectively; PNA-clamping assay: 92.86% and 86.79%).

4. Discussion {#sec4-jcm-09-02283}
=============

The ddPCR platform is an advanced digital PCR technology that has been used to detect and quantify target DNA or RNA in tissue or blood samples. ddPCR is a very sensitive method that can detect as little as 0.01% mutant DNA \[[@B4-jcm-09-02283]\]. Because ddPCR provides an absolute number of fluorescent droplets, clinical applications of the ddPCR platform require delineation between positive (mutant) and negative (wild-type) KRAS^G12/G13^ mutation status, which is critical for therapeutic decision-making \[[@B11-jcm-09-02283],[@B12-jcm-09-02283]\]. Previous studies reported various cutoffs for KRAS^G12/G13^ determined by ddPCR; Dong et al. \[[@B13-jcm-09-02283]\] set 0.02 to 0.56% cutoffs for multiple KRAS^G12/G13^ mutation site based on detection limit on their experiments of mixing mutant KRAS^G12/G13^ DNA to wild-type DNA; Vanova et al. \[[@B14-jcm-09-02283]\] determined an arbitrary 0.6% cutoff; Alcaide et al. \[[@B4-jcm-09-02283]\] set a MAF cutoff of 1%, which was a threshold above background gray-zone noisy; and Laurent-Puig et al. \[[@B15-jcm-09-02283]\] suggested a 1% threshold, which was a clinically relevant cutoff to discriminate a patient's prognosis.

The sensitive PCR method has the possibility to lead to false positive (FP) results. An FFPE sample is very commonly used for clinical sequencing because it is easy to match tumor and normal tissue in the slides and it can be stored at room temperature. However, sequencing from DNA-extracted FFPE samples can yield errors due to fragmentation of genomic DNA and chemical processing damage to the samples \[[@B5-jcm-09-02283]\]. The limit of detection (LOD) for detecting KRAS mutation was differently reported depending on the sample types; 0.05% for G12D and 0.01% for G12C using cancer cell lines with TaqMan MGB probes; 0.2% using FFPE CRAC samples with KRAS multiplex kit \[[@B13-jcm-09-02283],[@B16-jcm-09-02283]\]. We detected no mutant droplets using serums samples and 0 to 0.55% MAF using non-neoplastic FFPE colon samples. With 0.12% cutoff closed to LOD, the diagnostic value of KRAS^G12/G13^ detection of ddPCR yielded a high sensitivity (100%) and low specificity (30.61%). With 7.9% cutoff generated from ROC curve validated with KRAS^G12/G13^ wild-type samples, diagnostic value of ddPCR yielded a high sensitivity (84.38%) and high specificity (97.96%). We decided that 7.9% MAF cutoff might decrease the possibility of FP results and be more appropriate for clinical application using FFPE patient samples.

Cases with wild type by ddPCR KRAS^G12/G13^ mutation have the possibility of KRAS^G12/G13^ mutant type. The sanger sequencing detected KRAS^G12/G13^ mutation in cases with low MAF (0.17%\~1.78%) that 7.9% MAF cutoff can be rather high and can miss mutant cases with low MAF. We set arbitrary cutoff to increase the specificity to use ddPCR as a diagnostic assay using FFPE tissue samples. Considering the biggest merit of the ddPCR is the sensitivity, we need to set appropriate MAF cut offs depending on the sample types (blood or urine) and detection probes (TaqMan probe or multiplex kit). In a previous study, CRAC patients with below 1% MAF KRAS mutation showed more therapeutic response with anti-EGFR therapy than above 1% MAF KRAS mutation \[[@B15-jcm-09-02283]\]. Clinical significance can also be the standard to set clinical cutoff for MAF of the KRAS mutation.

ddPCR is a fluorescent probe-based PCR assay to partition sample DNA into \~20,000 droplets that fluorescence emitted from each droplet is measured to quantitate the number of target DNA molecules \[[@B17-jcm-09-02283]\]. The number of positive droplets is very sensitive to pipette handling during droplet generation, cartridge exchange, and minor changes in fluorescence color \[[@B18-jcm-09-02283]\]. Taylor et al. \[[@B19-jcm-09-02283]\] reported that ddPCR produced more consistent and reproducible data than quantitative PCR when they used samples with variable contamination. To estimate the consistency of the ddPCR platform using FFPE samples, we performed repetitive measurement of KRAS^G12/G13^. Three sets of measurements yielded seven discrepant results that 5 discordant cases raised at the first measurement and 2 cases were small-sized specimens (less than 1 cm). We guessed that an unaccustomed technique in pipette handling during droplet generation and small-sized specimens could be the reason. Low fractions of mutant DNA raised the possibility of false-positive or false-negative results. When using FFPE tissue samples, sensitivity could be limited by the amount of mutant DNA; however, in such a case, repetitive measurement could guarantee the results and increase diagnostic sensitivity. Statistically, ddPCR yielded an excellent intraclass correlation, allowing us to conclude that the ddPCR platform has the potential to be used as a sensitive and reliable method to detect KRAS^G12/G13^ mutation.

This study has some limitations. First, when developing ROC curves to calculate ddPCR cutoffs, we defined positive references based on results from Sanger sequencing. However, the mutational status assessed by Sanger sequencing did not represent the true properties of KRAS^G12/G13^ DNA in samples. However, the Sanger sequencing has been employed in diagnostic laboratories and is considered a gold standard for evaluating KRAS^G12/G13^ with high specificity. In addition, PNA-clamping is also commonly used in diagnostic laboratories for evaluating KRAS^G12/G13^ with high specificity \[[@B20-jcm-09-02283]\]. Comparing two methods to detect KRAS^G12/G13^ mutation, the concordant rate of the ddPCR and Sanger sequencing was 93% and the ddPCR and PNA-clamping assay was 89%. Sanger sequencing detected KRAS^G12/G13^ mutation in cases with low MAF by ddPCR (mean MAF = 0.4%). PNA clamping assay detected KRAS^G12/G13^ mutation in cases with MAF by ddPCR (mean MAF = 3.7%), however, showed wild type with high MAF by ddPCR (18.2% and 19.36%). The ddPCR showed more comparable results to Sanger sequencing. PNA clamping assay had the possibility of lower specificity compare to ddPCR and Sanger sequencing.

In a comparison of Sanger sequencing and PNA-clamping assay, ddPCR with applied clinical cutoff eliminated false-positive results and preserved high sensitivity (100%) and specificity (100%) relative to the Sanger sequencing and PNA-clamping assay. In comparison with NGS panel sequencing ([Supplementary Table S1](#app1-jcm-09-02283){ref-type="app"}), ddPCR and Sanger sequencing showed higher sensitivity (96.43% and 100%, respectively) and specificity (98.11% and 92.45%, respectively). NGS panel sequencing offered multiple gene screening including KRAS^G12/G13^ status, but showed a low sensitivity and positive predictive value. ddPCR, Sanger sequencing, and the PNA-clamping assay showed comparable results for detecting KRAS^G12/G13^ mutation, however, the required amount of DNA (1 μL) for ddPCR is much less than for Sanger sequencing (20 ng) and PNA-clamping assay (7 μL). This technical advantage is useful detecting KRAS^G12/G13^ mutation in small biopsied tissues or even liquid biopsy samples. Furthermore, the KRAS^G12/G13^ multiplex kit could not discriminate the mutation codon site and did not cover the full spectrum of mutation sites in KRAS. The ddPCR platform includes two fluorescence filters and supports at least duplex reactions. The development and optimization of higher-order multiplexing techniques for ddPCR are still required.

5. Conclusions {#sec5-jcm-09-02283}
==============

Determining KRAS mutational status has become crucial for successfully managing CRC patients, as well as in applications of anti-EGFR therapy. Furthermore, patients with the KRAS^G12/G13^ mutation tend to have more advanced tumors and shorter survival, implying that KRAS^G12/G13^ could be used as a prognostic factor \[[@B21-jcm-09-02283]\]. Thus, KRAS^G12/G13^ is a highly informative and useful marker for the management of CRAC. By allowing the optimal cutoff value to be defined, ddPCR has potential for use as a diagnostic tool that could improve diagnostic sensitivity and specificity. Because ddPCR has high sensitivity and reproducibility, it would be suitable for daily application in laboratories seeking to detect KRAS^G12/G13^ mutations in CRAC tissue samples.

The following are available online at <https://www.mdpi.com/2077-0383/9/7/2283/s1>: Table S1: Diagnostic value of KRA^G12/13^ mutation detection by ddPCR, Sanger sequencing, and PNA-clamping assay, and NGS panel sequencing (IonS5, Thermo Fisher Scientific).
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![Droplet digital polymerase chain reaction (ddPCR) workflow (**A**) and representative results of ddPCR for detection of KRAS^G12/13^. Channel 1: fluorescence measurement of mutant probe labeled with 6-fluorescein amidite (FAM). ((**B**) left) Channel 2; wild-type probe labeled with hexachlorofluorescein (HEX) ((**B**) right).](jcm-09-02283-g001){#jcm-09-02283-f001}

![Receiver operating characteristic (ROC) curves for ddPCR. Optimal cutoff criteria and the area under curve (AUC) results are shown. (**A**) ROC curves using KRAS results from KRAS mutant CRAC and non-neoplastic colon (**B**) ROC curves using KRAS results from KRAS mutant CRAC, KRAS wild CRAC, and non-neoplastic colon.](jcm-09-02283-g002){#jcm-09-02283-f002}

jcm-09-02283-t001_Table 1

###### 

Diagnostic value of KRAS^G12/13^ mutation by ddPCR depending on mutant cutoff criteria.

                KRAS Mutant CRAC & Non-Neoplastic Colon (0.12% Cutoff)   KRAS Mutant and KRAS Wild CRAC & Non-Neoplastic Colon (7.9% Cutoff)
  ------------- -------------------------------------------------------- ---------------------------------------------------------------------
  Sensitivity   100.0% (89.11--100.00)                                   84.38% (67.21--94.72)
  Specificity   30.61% (18.25--45.42)                                    97.96% (89.15--99.95)
  PPV           48.48% (43.87--53.13)                                    96.43% (79.42--99.47)
  NPV           100.0% (100.00--100.00)                                  90.57% (81.09--97.23)

CRAC, colorectal adenocarcinoma; PPV, positive predictive value; NPV, negative predictive value.

jcm-09-02283-t002_Table 2

###### 

Repeated KRAS^G12/13^ mutation detection in CRAC tissue by ddPCR.

  Sample ID   First KRAS ddPCR   Second KRAS ddPCR   Third KRAS ddPCR   Mean KRAS ddPCR                               
  ----------- ------------------ ------------------- ------------------ ----------------- ------- ----------- ------- -----------
  T1          0                  Wild-type           0                  Wild-type         0       Wild-type   0       Wild-type
  T2          0                  Wild-type           0.07               Wild-type         0       Wild-type   0.02    Wild-type
  T3          0.05               Wild-type           0                  Wild-type         0       Wild-type   0.02    Wild-type
  T4          0.05               Wild-type           0                  Wild-type         0       Wild-type   0.02    Wild-type
  T5          0.04               Wild-type           0                  Wild-type         0.04    Wild-type   0.03    Wild-type
  T6          0                  Wild-type           0                  Wild-type         0.11    Wild-type   0.04    Wild-type
  T7          0.04               Wild-type           0.04               Wild-type         0.09    Wild-type   0.05    Wild-type
  T8          0                  Wild-type           0.19               Wild-type         0       Wild-type   0.06    Wild-type
  T9          0.08               Wild-type           0.13               Wild-type         0       Wild-type   0.07    Wild-type
  T10         0                  Wild-type           0.14               Wild-type         0.1     Wild-type   0.08    Wild-type
  T11         0.09               Wild-type           0.09               Wild-type         0.07    Wild-type   0.09    Wild-type
  T12         0                  Wild-type           0.15               Wild-type         0.11    Wild-type   0.09    Wild-type
  T13         0.1                Wild-type           0.07               Wild-type         0.1     Wild-type   0.09    Wild-type
  T14         0                  Wild-type           0.13               Wild-type         0.19    Wild-type   0.11    Wild-type
  T15         0                  Wild-type           0.08               Wild-type         0.26    Wild-type   0.11    Wild-type
  T16         0.11               Wild-type           0.27               Wild-type         0       Wild-type   0.12    Wild-type
  T17         0                  Wild-type           0.2                Wild-type         0.2     Wild-type   0.13    Wild-type
  T18         0.02               Wild-type           0.15               Wild-type         0.27    Wild-type   0.15    Wild-type
  T19         0.21               Wild-type           0.12               Wild-type         0.17    Wild-type   0.16    Wild-type
  T20         0                  Wild-type           0.13               Wild-type         0.36    Wild-type   0.16    Wild-type
  T21         0.11               Wild-type           0.11               Wild-type         0.25    Wild-type   0.16    Wild-type
  T22         0.09               Wild-type           0                  Wild-type         0.4     Wild-type   0.16    Wild-type
  T23         0                  Wild-type           0.16               Wild-type         0.36    Wild-type   0.17    Wild-type
  T24         0.07               Wild-type           0.11               Wild-type         0.33    Wild-type   0.17    Wild-type
  T25         0                  Wild-type           0.28               Wild-type         0.3     Wild-type   0.19    Wild-type
  T26         0                  Wild-type           0.46               Wild-type         0.12    Wild-type   0.19    Wild-type
  T27         0.19               Wild-type           0.23               Wild-type         0.24    Wild-type   0.22    Wild-type
  T28         0                  Wild-type           0.48               Wild-type         0.26    Wild-type   0.25    Wild-type
  T29         0.3                Wild-type           0.16               Wild-type         0.31    Wild-type   0.26    Wild-type
  T30         0.28               Wild-type           0.19               Wild-type         0.41    Wild-type   0.29    Wild-type
  T31         0.26               Wild-type           0.09               Wild-type         0.54    Wild-type   0.3     Wild-type
  T32         0.06               Wild-type           0.53               Wild-type         0.3     Wild-type   0.3     Wild-type
  T33         0                  Wild-type           0.49               Wild-type         0.45    Wild-type   0.31    Wild-type
  T34         0.34               Wild-type           0.23               Wild-type         0.39    Wild-type   0.32    Wild-type
  T35         0.06               Wild-type           0.44               Wild-type         0.5     Wild-type   0.33    Wild-type
  T36         0.07               Wild-type           0.12               Wild-type         0.79    Wild-type   0.33    Wild-type
  T37         0.14               Wild-type           0.37               Wild-type         0.47    Wild-type   0.33    Wild-type
  T38         0.04               Wild-type           0.55               Wild-type         0.58    Wild-type   0.39    Wild-type
  T39         0                  Wild-type           0.75               Wild-type         0.51    Wild-type   0.42    Wild-type
  T40         0.27               Wild-type           0.4                Wild-type         0.76    Wild-type   0.48    Wild-type
  T41         0                  Wild-type           0.73               Wild-type         0.71    Wild-type   0.48    Wild-type
  T42         0.22               Wild-type           0                  Wild-type         1.4     Wild-type   0.54    Wild-type
  T43         0.21               Wild-type           0.6                Wild-type         0.85    Wild-type   0.55    Wild-type
  T44         0.7                Wild-type           1.08               Wild-type         0.69    Wild-type   0.82    Wild-type
  T45         2.65               Wild-type           0                  Wild-type         0       Wild-type   0.88    Wild-type
  T46         0.97               Wild-type           0.8                Wild-type         0.97    Wild-type   0.91    Wild-type
  T47         0.52               Wild-type           1.38               Wild-type         1.23    Wild-type   1.04    Wild-type
  T48         3.69               Wild-type           1                  Wild-type         0.66    Wild-type   1.78    Wild-type
  T49         5.76               Wild-type           0.49               Wild-type         0.16    Wild-type   2.14    Wild-type
  T50         5.79               Wild-type           1.04               Wild-type         0.42    Wild-type   2.42    Wild-type
  T51         7.42               Wild-type           1.56               Wild-type         3.01    Wild-type   4       Wild-type
  \* T52      2.17               Wild-type           5.62               Wild-type         8.65    Mutant      5.48    Wild-type
  \* T53      3.61               Wild-type           9.11               Mutant            9.87    Mutant      7.53    Wild-type
  \* T54      5.48               Wild-type           7.74               Wild-type         10.49   Mutant      7.9     Mutant
  T55         13.94              Mutant              15.08              Mutant            13.29   Mutant      14.1    Mutant
  \* T56      0.75               Wild-type           22.36              Mutant            22.88   Mutant      15.33   Mutant
  T57         10.48              Mutant              17.56              Mutant            18.47   Mutant      15.51   Mutant
  \* T58      4.71               Wild-type           22.75              Mutant            21.34   Mutant      16.27   Mutant
  T59         13.39              Mutant              20.33              Mutant            20.88   Mutant      18.2    Mutant
  T60         16.62              Mutant              18.76              Mutant            21.23   Mutant      18.87   Mutant
  T61         16.58              Mutant              17.12              Mutant            24.37   Mutant      19.36   Mutant
  T62         15.04              Mutant              21.44              Mutant            22.65   Mutant      19.71   Mutant
  T63         10.82              Mutant              24.39              Mutant            28.47   Mutant      21.23   Mutant
  T64         9.23               Mutant              26.74              Mutant            28      Mutant      21.32   Mutant
  \* T65      2.04               Wild-type           29.01              Mutant            38.62   Mutant      23.22   Mutant
  T66         15.63              Mutant              27.81              Mutant            29.46   Mutant      24.3    Mutant
  T67         27.78              Mutant              23.06              Mutant            23.44   Mutant      24.76   Mutant
  T68         24.88              Mutant              30.54              Mutant            31.24   Mutant      28.89   Mutant
  T69         25                 Mutant              32.61              Mutant            31.67   Mutant      29.76   Mutant
  T70         9.47               Mutant              46.99              Mutant            50.34   Mutant      35.6    Mutant
  T71         34.96              Mutant              34.48              Mutant            38.13   Mutant      35.85   Mutant
  T72         20.1               Mutant              42.43              Mutant            45.5    Mutant      36.01   Mutant
  T73         38.23              Mutant              32.7               Mutant            38.13   Mutant      36.36   Mutant
  T74         36.08              Mutant              40.95              Mutant            43.71   Mutant      40.25   Mutant
  \* T75      4.29               Wild-type           55.56              Mutant            60.95   Mutant      40.27   Mutant
  T76         30.18              Mutant              50.53              Mutant            49.34   Mutant      43.35   Mutant
  T77         41.87              Mutant              42.24              Mutant            46.7    Mutant      43.6    Mutant
  T78         41.14              Mutant              44.78              Mutant            48.95   Mutant      44.96   Mutant
  T79         60.77              Mutant              45.28              Mutant            49.33   Mutant      51.79   Mutant
  T80         53.88              Mutant              60.45              Mutant            58.23   Mutant      57.52   Mutant
  T81         83.77              Mutant              78.03              Mutant            81.71   Mutant      81.17   Mutant

ddPCR, digital droplet PCR, \* Cases yielded discrepant results regarding KRAS^G12/G13^ mutation status. MAF, mutant allele frequency.

jcm-09-02283-t003_Table 3

###### 

Diagnostic value of repeated measurement of KRAS^G12/13^ mutation by ddPCR.

                First ddPCR   Second ddPCR   Third ddPCR   Mean ddPCR
  ------------- ------------- -------------- ------------- ------------
  Sensitivity   71.88%        84.38%         84.38%        84.38%
  Specificity   100%          97.96%         93.88%        97.96%
  PPV           100%          96.43%         90.00%        96.43%
  NPV           84.48%        90.57%         90.20%        90.57%

PPV, positive predictive value; NPV, negative predictive value.
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###### 

Comparative analysis of KRAS^G12/13^ mutation detection by ddPCR, Sanger sequencing, and peptide nucleic acid (PNA) clamping assay.

  Sample ID   KRAS ddPCR   KRAS ddPCR   KRAS Sanger    KRAS PNA
  ----------- ------------ ------------ -------------- --------------
  T1          0.00         Wild-type    Wild-type      Wild-type
  T2          0.02         Wild-type    Wild-type      Wild-type
  T3          0.02         Wild-type    Wild-type      Wild-type
  T4          0.02         Wild-type    Wild-type      Wild-type
  T5          0.03         Wild-type    Wild-type      Wild-type
  T6          0.04         Wild-type    Wild-type      Wild-type
  T7          0.05         Wild-type    Wild-type      Wild-type
  T8          0.06         Wild-type    Wild-type      Wild-type
  T9          0.07         Wild-type    Wild-type      Wild-type
  T10         0.08         Wild-type    Wild-type      Wild-type
  T11         0.09         Wild-type    Wild-type      Wild-type
  T12         0.09         Wild-type    Wild-type      Wild-type
  T13         0.09         Wild-type    Wild-type      Wild-type
  T14         0.11         Wild-type    Wild-type      Wild-type
  \* T15      0.11         Wild-type    Wild-type      \* Mutant
  T16         0.12         Wild-type    Wild-type      Wild-type
  T17         0.13         Wild-type    Wild-type      Wild-type
  T18         0.15         Wild-type    Wild-type      Wild-type
  T19         0.16         Wild-type    Wild-type      Wild-type
  T20         0.16         Wild-type    Wild-type      Wild-type
  T21         0.16         Wild-type    Wild-type      Wild-type
  T22         0.16         Wild-type    Wild-type      Wild-type
  \* T23      0.17         Wild-type    \* Mutant      Wild-type
  T24         0.17         Wild-type    Wild-type      Wild-type
  T25         0.19         Wild-type    Wild-type      Wild-type
  T26         0.19         Wild-type    Wild-type      Wild-type
  T27         0.22         Wild-type    Wild-type      Wild-type
  T28         0.25         Wild-type    Wild-type      Wild-type
  \* T29      0.26         Wild-type    \* Mutant      Wild-type
  T30         0.29         Wild-type    Wild-type      Wild-type
  T31         0.3          Wild-type    Wild-type      Wild-type
  T32         0.3          Wild-type    Wild-type      Wild-type
  T33         0.31         Wild-type    Wild-type      Wild-type
  T34         0.32         Wild-type    Wild-type      Wild-type
  T35         0.33         Wild-type    Wild-type      Wild-type
  T36         0.33         Wild-type    Wild-type      Wild-type
  T37         0.33         Wild-type    Wild-type      Wild-type
  \* T38      0.39         Wild-type    \* Mutant      Wild-type
  T39         0.42         Wild-type    Wild-type      Wild-type
  T40         0.48         Wild-type    Wild-type      Wild-type
  T41         0.48         Wild-type    Wild-type      Wild-type
  \* T42      0.54         Wild-type    \* Mutant      Wild-type
  T43         0.55         Wild-type    Wild-type      Wild-type
  T44         0.82         Wild-type    Wild-type      Wild-type
  T45         0.88         Wild-type    Wild-type      Wild-type
  T46         0.91         Wild-type    Wild-type      Wild-type
  \* T47      1.04         Wild-type    Wild-type      \* Mutant
  \* T48      1.78         Wild-type    \* Mutant      Wild-type
  \* T49      2.14         Wild-type    Wild-type      \* Mutant
  \* T50      2.42         Wild-type    Wild-type      \* Mutant
  \* T51      4.00         Wild-type    Wild-type      \* Mutant
  \* T52      5.48         Wild-type    Wild-type      \* Mutant
  \* T53      7.53         Wild-type    Wild-type      \* Mutant
  \* T54      7.90         Mutant       \* Wild-type   Mutant
  T55         14.1         Mutant       Mutant         Mutant
  T56         15.33        Mutant       Mutant         Mutant
  T57         15.51        Mutant       Mutant         Mutant
  T58         16.27        Mutant       Mutant         Mutant
  \* T59      18.20        Mutant       Mutant         \* Wild-type
  T60         18.87        Mutant       Mutant         Mutant
  \* T61      19.36        Mutant       Mutant         \* Wild-type
  T62         19.71        Mutant       Mutant         Mutant
  T63         21.23        Mutant       Mutant         Mutant
  T64         21.32        Mutant       Mutant         Mutant
  T65         23.22        Mutant       Mutant         Mutant
  T66         24.30        Mutant       Mutant         Mutant
  T67         24.76        Mutant       Mutant         Mutant
  T68         28.89        Mutant       Mutant         Mutant
  T69         29.76        Mutant       Mutant         Mutant
  T70         35.60        Mutant       Mutant         Mutant
  T71         35.85        Mutant       Mutant         Mutant
  T72         36.01        Mutant       Mutant         Mutant
  T73         36.36        Mutant       Mutant         Mutant
  T74         40.25        Mutant       Mutant         Mutant
  T75         40.27        Mutant       Mutant         Mutant
  T76         43.35        Mutant       Mutant         Mutant
  T77         43.60        Mutant       Mutant         Mutant
  T78         44.96        Mutant       Mutant         Mutant
  T79         51.79        Mutant       Mutant         Mutant
  T80         57.52        Mutant       Mutant         Mutant
  T81         81.17        Mutant       Mutant         Mutant

\* Cases yielded discrepant results regarding KRAS^G12/G13^ mutation status. MAF, mutant allele frequency.
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###### 

Diagnostic value of KRA^G12/13^ mutation detection by ddPCR, Sanger sequencing, and PNA-clamping assay.

                Detection of KRA^G12/13^ Mutation            
  ------------- ----------------------------------- -------- --------
  Sensitivity   100%                                96.43%   92.86%
  Specificity   100%                                90.57%   86.79%
  PPV           100%                                84.38%   78.79%
  NPV           100%                                97.96%   95.83%

PPV, positive predictive value; NPV, negative predictive value.

[^1]: These authors contributed equally to this work.
